AU2124800A - Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents - Google Patents

Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents Download PDF

Info

Publication number
AU2124800A
AU2124800A AU21248/00A AU2124800A AU2124800A AU 2124800 A AU2124800 A AU 2124800A AU 21248/00 A AU21248/00 A AU 21248/00A AU 2124800 A AU2124800 A AU 2124800A AU 2124800 A AU2124800 A AU 2124800A
Authority
AU
Australia
Prior art keywords
aryl
methyl
alkyl
cancer
membered heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21248/00A
Other languages
English (en)
Inventor
Bingwei Vera Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2124800A publication Critical patent/AU2124800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU21248/00A 1999-02-11 2000-02-04 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents Abandoned AU2124800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11970299P 1999-02-11 1999-02-11
US60119702 1999-02-11
PCT/IB2000/000121 WO2000047574A1 (en) 1999-02-11 2000-02-04 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
AU2124800A true AU2124800A (en) 2000-08-29

Family

ID=22385869

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21248/00A Abandoned AU2124800A (en) 1999-02-11 2000-02-04 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents

Country Status (39)

Country Link
US (3) US6258824B1 (OSRAM)
EP (1) EP1150973B1 (OSRAM)
JP (3) JP4090200B2 (OSRAM)
KR (1) KR20010102073A (OSRAM)
CN (1) CN1340051A (OSRAM)
AP (1) AP2001002241A0 (OSRAM)
AR (1) AR028985A1 (OSRAM)
AT (1) ATE297916T1 (OSRAM)
AU (1) AU2124800A (OSRAM)
BG (1) BG105860A (OSRAM)
BR (1) BR0008202A (OSRAM)
CA (1) CA2362394C (OSRAM)
CO (1) CO5140097A1 (OSRAM)
CZ (1) CZ20012910A3 (OSRAM)
DE (1) DE60020812T2 (OSRAM)
DZ (1) DZ3009A1 (OSRAM)
EA (1) EA200100766A1 (OSRAM)
EE (1) EE200100425A (OSRAM)
ES (1) ES2243228T3 (OSRAM)
GT (1) GT200000014A (OSRAM)
HK (1) HK1042096A1 (OSRAM)
HN (1) HN2000000019A (OSRAM)
HR (1) HRP20010574A2 (OSRAM)
HU (1) HUP0105231A3 (OSRAM)
ID (1) ID29584A (OSRAM)
IL (1) IL144307A0 (OSRAM)
IS (1) IS5997A (OSRAM)
MA (1) MA26718A1 (OSRAM)
NO (1) NO20013909L (OSRAM)
OA (1) OA11833A (OSRAM)
PA (1) PA8490601A1 (OSRAM)
PE (1) PE20001464A1 (OSRAM)
PL (1) PL349839A1 (OSRAM)
SK (1) SK11002001A3 (OSRAM)
SV (1) SV2001000020A (OSRAM)
TN (1) TNSN00028A1 (OSRAM)
TR (2) TR200201296T2 (OSRAM)
WO (1) WO2000047574A1 (OSRAM)
ZA (1) ZA200106520B (OSRAM)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100591603B1 (ko) * 1998-07-06 2006-06-20 얀센 파마슈티카 엔.브이. 생체내 방사선 감작성을 갖는 파네실 단백질 트랜스퍼라제억제제
BR0008202A (pt) * 1999-02-11 2002-02-19 Pfizer Prod Inc Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
TR200401209T4 (tr) * 1999-11-05 2004-07-21 Cytovia, Inc. Kaspazların aktivatörleri ve apoptoz endüserleri olarak yer değiştiren 4H-kromen ve analogları ile bunların kullanımı
TR200400342T4 (tr) * 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2001054688A1 (en) * 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002024682A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
WO2002024686A2 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
CA2421782A1 (en) * 2000-10-02 2002-04-11 Janssen Pharmaceutica N.V. Quinoline and quinolinone derivatives as metabotropic glutamate receptor antagonists
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
PT1351954E (pt) * 2000-12-27 2006-09-29 Janssen Pharmaceutica Nv Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
EP1347966B1 (en) 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
WO2002092076A1 (en) 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
CN100564377C (zh) * 2001-05-16 2009-12-02 西托维亚公司 用作半胱天冬酶激活剂和细胞凋亡诱导剂的取代的4h-色烯和类似物及其应用
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
AU2002358677B2 (en) 2001-12-19 2008-02-07 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
EP1490065B1 (en) * 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
KR101061561B1 (ko) * 2002-03-29 2011-09-02 얀센 파마슈티카 엔.브이. 대사자극성 글루타메이트 수용체 리간드로서 방사능표지된 퀴놀린 및 퀴놀리논 유도체 및 그의 용도
CA2481480C (en) 2002-04-15 2011-04-12 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
WO2003097806A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2003241482A1 (en) 2002-05-16 2003-12-02 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
BR0317548A (pt) * 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
WO2004076412A2 (en) 2003-02-26 2004-09-10 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
TW200504057A (en) * 2003-02-27 2005-02-01 Chugai Pharmaceutical Co Ltd Benzothiophene derivative
WO2005009967A2 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
MX2007001986A (es) * 2004-08-26 2007-05-10 Pfizer Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
AU2005294430A1 (en) * 2004-10-07 2006-04-20 Cytovia, Inc. Substituted N-aryl-1H-pyrazolo[3,4-b]quinolin-4-amines and analogs as activators of caspases and inducers of apoptosis
EP1920048A4 (en) 2005-07-29 2009-12-09 Childrens Hosp Medical Center GTASE INHIBITORS AND USE METHOD AND CRYSTAL STRUCTURE OF RAC-1 GTASE
MY164457A (en) 2005-09-07 2017-12-15 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
ATE533057T1 (de) 2005-09-20 2011-11-15 Osi Pharm Inc Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
US20070213366A1 (en) 2005-12-23 2007-09-13 Justman Craig J Treatment of Synucleinopathies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP2056874B1 (en) 2006-08-21 2012-09-19 F. Hoffmann-La Roche AG Tumor therapy with an anti-vegf antibody
EP2162450B1 (en) * 2007-05-23 2015-02-25 Allergan, Inc. ((bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
DK2155733T3 (da) * 2007-05-23 2012-10-29 Allergan Inc Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
US8129356B2 (en) * 2007-10-01 2012-03-06 Vanderbilt University Bmx mediated signal transduction in irradiated vascular endothelium
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
CN102307875A (zh) 2009-02-09 2012-01-04 苏伯俭股份有限公司 吡咯并嘧啶基axl激酶抑制剂
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
JP6250686B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのヘテロアリール結合させたキノリニルモジュレータ
ME02794B (me) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
ES2770727T3 (es) 2013-10-15 2020-07-02 Janssen Pharmaceutica Nv Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
JP6877429B2 (ja) 2015-12-03 2021-05-26 アジオス ファーマシューティカルズ， インコーポレイテッド Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
CN108003150A (zh) * 2016-10-31 2018-05-08 河南工业大学 4-杂芳基喹啉酮衍生物的制备方法及其应用
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
JP7718659B2 (ja) 2019-08-16 2025-08-05 チルドレンズ ホスピタル メディカル センター Ｃｄｃ４２特異的阻害剤で対象を治療する方法
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732531A1 (de) * 1977-07-19 1979-02-01 Hoechst Ag Imidazolcarbonsaeuren und deren derivate
US4835154A (en) * 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US5053543A (en) * 1990-11-28 1991-10-01 Glaxo Inc. Synthesis of 2-aminobenzophenones
US5136085A (en) * 1990-11-28 1992-08-04 Glaxo Inc. Synthesis of 2-aminobenzophenones
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
ATE321757T1 (de) * 1995-12-08 2006-04-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren
CA2290992C (en) * 1997-06-02 2008-02-12 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
JP3495706B2 (ja) 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
BR0008202A (pt) * 1999-02-11 2002-02-19 Pfizer Prod Inc Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer

Also Published As

Publication number Publication date
US6388092B2 (en) 2002-05-14
PL349839A1 (en) 2002-09-23
CA2362394C (en) 2006-01-17
WO2000047574A1 (en) 2000-08-17
HUP0105231A2 (hu) 2002-04-29
IL144307A0 (en) 2002-05-23
CA2362394A1 (en) 2000-08-17
US20020120145A1 (en) 2002-08-29
BG105860A (en) 2002-03-29
ES2243228T3 (es) 2005-12-01
IS5997A (is) 2001-07-10
JP2004182741A (ja) 2004-07-02
EA200100766A1 (ru) 2002-02-28
EP1150973A1 (en) 2001-11-07
AR028985A1 (es) 2003-06-04
EE200100425A (et) 2002-12-16
DE60020812T2 (de) 2006-05-04
JP4216740B2 (ja) 2009-01-28
US20020019530A1 (en) 2002-02-14
MA26718A1 (fr) 2004-12-20
DE60020812D1 (de) 2005-07-21
PA8490601A1 (es) 2002-07-30
TR200201296T2 (tr) 2002-07-22
SK11002001A3 (sk) 2002-05-09
JP4090200B2 (ja) 2008-05-28
TNSN00028A1 (fr) 2005-11-10
KR20010102073A (ko) 2001-11-15
PE20001464A1 (es) 2000-12-20
NO20013909L (no) 2001-10-08
HK1042096A1 (zh) 2002-08-02
CZ20012910A3 (cs) 2002-02-13
JP2005002124A (ja) 2005-01-06
AP2001002241A0 (en) 2001-09-30
ATE297916T1 (de) 2005-07-15
OA11833A (en) 2005-08-23
ZA200106520B (en) 2002-08-26
EP1150973B1 (en) 2005-06-15
TR200201297T2 (tr) 2002-06-21
US6710209B2 (en) 2004-03-23
US6258824B1 (en) 2001-07-10
SV2001000020A (es) 2001-11-08
ID29584A (id) 2001-09-06
CO5140097A1 (es) 2002-03-22
HUP0105231A3 (en) 2003-01-28
NO20013909D0 (no) 2001-08-10
HRP20010574A2 (en) 2002-12-31
BR0008202A (pt) 2002-02-19
CN1340051A (zh) 2002-03-13
DZ3009A1 (fr) 2004-03-27
GT200000014A (es) 2001-08-03
JP2002536444A (ja) 2002-10-29
HN2000000019A (es) 2001-07-30

Similar Documents

Publication Publication Date Title
EP1150973B1 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6596735B1 (en) Quinoline derivatives useful for inhibiting farnesyl protein transferase
CA2398353C (en) Anticancer compound and enantiomer separation method useful for synthesizing said compound
US6844357B2 (en) Substituted quinolin-2-one derivatives useful as antiproliferative agents
US6586447B1 (en) 3,3-disubstituted-oxindole derivatives useful as anticancer agents
KR100816166B1 (ko) 항증식제로서 유용한 신규한 벤조이미다졸린 유도체
CA2381513C (en) Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
CA2586175C (en) Anticancer compound and enantiomer separation method useful for synthesizing said compound
MXPA01008154A (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
ZA200501353B (en) Novel benzoimidazole derivatives useful as antiproliferative agents

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted